Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
Status:
Recruiting
Trial end date:
2023-03-29
Target enrollment:
Participant gender:
Summary
This phase I/II trial investigates the best dose and effect of alisertib in combination with
pembrolizumab in treating patients with Rb-deficient head and neck squamous cell cancer.
Alisertib may help block the growth of cancer.. Immunotherapy with monoclonal antibodies,
such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere
with the ability of tumor cells to grow and spread. Giving alisertib in combination with
pembrolizumab may help control Rb-deficient head and neck squamous cell cancer. HPV positive
head and neck cancers are Rb-deficient.